GPC actively promotes the rejuvenation of its time-honored brands and creates a series of "superstar varieties".
GPC promotes the integration of traditional Chinese medicine into clothing, food, housing and transportation, and launches the fashionable traditional Chinese medicine toothpaste "Baiyun Toothpaste".
Recently, Li Chuyuan, Secretary of the Party Committee and Chairman of Guangzhou Pharmaceutical Group, led a team to Huazhou, Maoming, Guangdong Province to investigate and investigate the orange industry, in the process of investigation, Li Chuyuan said that the development momentum of the orange industry is good, and the Guangzhou Pharmaceutical Group will develop new quality productivity according to local conditions through science and technology and brand empowerment, promote the development of orange red products, and make the orange red into the traditional Chinese medicine IP of Guangzhou Medicine, promote the development of orange red into a fashion industry, and further leverage the integrated development of primary, secondary and tertiary industries.
The development of orange red is a specific practice of GPC in cultivating and developing new quality productivity of traditional Chinese medicine. Article 1 of the key tasks of the 2024 government work report points out that it is necessary to vigorously promote the construction of a modern industrial system and accelerate the development of new quality productive forces. For the biomedical industry, the development of new quality productivity to promote industrial transformation and upgrading has become the first priority, among which Guangzhou Pharmaceutical Group has made a layout in advance.
As the world's first and only Fortune 500 company with traditional Chinese medicine as its main business, GPC will accelerate the development of new quality productivity, implement the leading project of scientific and technological innovation, strengthen key technology research, drive the research and development of innovative drugs to improve quality and efficiency, and actively promote digital transformation, create a new benchmark for the integration of digital and real in the pharmaceutical and health industry, and strive to create more traditional Chinese medicine IP.
It is understood that GPC has always adhered to the leadership of the manufacturing industry and has continuously handed over new answers to high-quality development. Last year, GPC achieved nearly double-digit growth in revenue and profit, and was listed on the Fortune Global 500 list for three consecutive years, jumping 41 places to 426th in 2023, and becoming the only Chinese company to be included in the pharmaceutical sub-industry list.
Li Chuyuan said that this year, GPC will fully implement the spirit of the 20th National Congress of the Communist Party of China, focus on the development theme of "Digital Economy Year", and move towards building a world-class comprehensive biomedical group, so as to lay a solid foundation for Chinese modernization.
From innovation-driven development to embracing the digital economy
GPC is speeding up the formation of new quality productivity
Innovation is the "cornerstone" for biopharmaceutical enterprises to maintain competitiveness and vitality, and GPC has deepened the implementation of the innovation-driven development strategy and comprehensively promoted high-level scientific and technological self-reliance and self-reliance, so as to accelerate the formation of new quality productivity.
At present, GPC has established nearly 90 scientific research platforms at all levels, including 8 state-level scientific research institutions, including the only "National Canine Laboratory Animal Resource Bank" in China and the only national engineering research center in the field of traditional Chinese medicine in Guangdong Province. Baidi Biotechnology Co., Ltd. and Yingkang Co., Ltd. are state-level specialized and new "little giant" enterprises, and Baiyunshan Hanfang Company has been shortlisted for the list of "Science and Technology Reform Enterprises" by the State-owned Assets Supervision and Administration Commission of the State Council.
Innovation and scientific research are inseparable from talent-driven, and GPC actively promotes the construction of an innovative talent system, and has established a high-level talent team composed of 3 Nobel Prize winners, 22 domestic and foreign academicians and masters of traditional Chinese medicine, 72 senior (professor-level) titles, 336 associate senior titles, and more than 120 doctors and postdoctoral fellows. It is precisely because of the leadership of innovative talents that at present, the group has more than 200 research projects, including 21 innovative drug projects, a record high, and a number of innovative drug projects such as self-developed Class 1 new Chinese medicine have obtained clinical trial approval, and new advantages for development are constantly emerging.
In the process of developing new quality productivity, digitalization is an inevitable trend in the transformation of the biomedical and health industry. This year, GPC actively embraced the "digital economy" and grasped the new opportunities of digital transformation. It is understood that 2024 will be designated as the "Year of Digital Economy" by GPC, and four digital projects will be implemented: business digitalization, management digitalization, decision-making digitalization, and operation digitalization, and efforts will be made to improve the quality and efficiency of development.
Driven by seizing the opportunity of "digital economy", GPC has established the first new public institution of state-owned enterprises in Guangzhou, "GPC Digital Economy Research Institute", Baiyunshan Zhongyi Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Co., Ltd., has been selected into the 2023 Industrial Internet Pilot Demonstration List of the Ministry of Industry and Information Technology, and Guangzhou Pharmaceutical Smart Logistics Center is one of the modern pharmaceutical logistics smart distribution hubs with the highest automation, the strongest intelligence and the most new technology applications in China.
Implement the "manufacturing master" and create traditional Chinese medicine IP
We will make every effort to build a "whole chain" modern industrial system
In the process of accelerating the development of new quality productivity, GPC, as the "chain master" enterprise of biomedicine, is implementing the "manufacturing master" and making every effort to build an industrial ecosystem.
At present, GPC has formed a pattern of developing the "headquarters economy" in Liwan, Guangzhou, building the Baiyunshan biomedical R&D and sales headquarters of Guangzhou Pharmaceutical Baiyunshan in Guangzhou International Biological Island, building the China Time-honored Brand Industrial Park in Zhongluotan, Baiyun, Guangzhou, laying out the health care and cultural tourism industry in Guangzhou Tonghe Area, building a large health industry base in Nansha, Guangzhou, and laying out the production base of chemical APIs in Zhuhai, forming a full-chain layout of the biomedical industry.
Driven by the layout of the whole chain, GPC has achieved high-quality development of its four major business segments, including "Great Southern Medicine", "Great Health", "Big Commerce" and "Big Medical", driving the innovation and development of more than 30 member companies, and its 12 time-honored brands such as Chen Liji, the "world's longest-lived pharmaceutical factory", and "Wang Laoji", the ancestor of herbal tea, and 10 century-old brands have frequently come out of the circle and radiated new vitality.
It is worth noting that GPC also actively promotes the concept of "fashionable Chinese medicine" and actively builds traditional Chinese medicine IP. Including the above-mentioned orange industry, GPC promotes the popularization, modernization, popularization, internationalization, industrialization and fashion of traditional Chinese medicine by integrating the traditional Chinese medicine industry into "clothing, food, housing and transportation".
Among them, Guangzhou Pharmaceutical Group has created the country's first "fashionable traditional Chinese medicine" toothpaste - Baiyun toothpaste. During the two sessions of the National People's Congress this year, when Li Chuyuan talked about the modernization of traditional Chinese medicine in the plenary meeting of the Guangdong delegation, he used Baiyun toothpaste as an example to show how to carry out innovation in the traditional Chinese medicine industry. In addition, Guangzhou Pharmaceutical Group is building the Lingnan Museum of Traditional Chinese Medicine on the basis of Shennong Thatched Cottage, and plans to build a national first-class museum and a national 5A-level scenic spot to create a new landmark of traditional Chinese medicine in Guangdong.
It is worth noting that GPC also actively plays a leading role in driving and helping leading enterprises.
In the past few years, Guangzhou Pharmaceutical Group has actively played the advantages of leading enterprises in the industry and the role of industrial investors to promote the coordinated development of its enterprises and Kangmei Pharmaceutical, and help Kangmei Pharmaceutical Co., Ltd. to be reborn and rejuvenated, Kangmei Pharmaceutical Co., Ltd. will make a profit of about 100 million yuan in 2023, turning losses into profits, making a historic breakthrough, and opening a new journey of high-quality development of New Kangmei.
Based in the Guangdong-Hong Kong-Macao Greater Bay Area, it has set up an international headquarters in Macao
Help China's biopharmaceutical industry go overseas
This year marks the 5th anniversary of the release of the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area, as one of the regions with the highest degree of openness and the strongest economic vitality in China, based on the new positioning of "one point and two places", the Guangdong-Hong Kong-Macao Greater Bay Area has accelerated the gathering of innovative resources and actively built a modern industrial system with international competitiveness.
The construction of the Guangdong-Hong Kong-Macao Greater Bay Area will help the industry go overseas, and Guangzhou Pharmaceutical Group will strive to be the "vanguard" of the construction of the Guangdong-Hong Kong-Macao Greater Bay Area to accelerate the layout.
GPC has set up its international headquarters in Macau, and is committed to building a new growth pole for the pharmaceutical industry with international competitiveness leading the Guangdong-Hong Kong-Macao Greater Bay Area, radiating Southeast Asia and Portuguese-speaking countries. The first project is to cooperate with the team of Academician Zhong Nanshan and Macau University of Science and Technology to promote the industrialization of the latest scientific research achievements of Baiyun Mountain Banlangen in Macao. In recent years, GPC has built the first GMP Chinese medicine pharmaceutical factory in Macao, GPC International (Macau) Qingzhou Pharmaceutical Factory, and obtained the first Chinese medicine manufacturing license, the first drug approval and the first GMP certificate for Chinese medicine manufacturing since the implementation of the Law on Pharmaceutical Activities and Registration of Chinese Proprietary Chinese Medicines in the Macao Special Administrative Region.
At the same time, GPC is also deepening its layout in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, and projects such as the Zhuhai Hengqin Branch of the International Engineering Research Center for the Modernization of Traditional Chinese Medicine Extraction and Separation Process, and the Zhuhai Hengqin Pharmaceutical Supply Chain of GPC are all progressing steadily.
In addition to the layout of the Guangdong-Hong Kong-Macao Greater Bay Area, GPC is also actively expanding the "global circle of friends" and strengthening international cooperation, so as to realize the "going overseas" of the industry.
In the past two years, GPC has visited Thailand, Singapore, Canada, the United States, Fiji, Germany, Greece, Italy and other countries, jointly established a 1 billion yuan industrial fund with WBA's wholly-owned subsidiary and Meihua, becoming the first qualified foreign limited partner pilot fund in Guangzhou, cooperated with Thailand Global Group to develop markets, and reached strategic cooperation with Chinese herbal medicine suppliers in Indonesia, Russia and other countries.
In addition, GPC promotes the acceleration of GPC's famous products to the international market. Wanglaoji Herbal Tea has been certified as the world's No. 1 natural plant beverage in terms of sales, and the international brand logo "WALOVI" has been launched, and the export growth trend is gratifying.
In the face of a new round of scientific and technological revolution and new opportunities for industrial transformation, Li Chuyuan said that in 2024, GPC will promote the mutual promotion of industry and technology, accelerate the development of new quality productivity, strive to achieve double-digit growth in 2024, promote high-quality development to a new level, and contribute to the construction of a healthy China.
Plate making: Li Zhiqi, Zou Hongxiang, Huang Yongwen